Innate Pharma S.A. IPHYF
1.51 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
2.18 Day range 2.25
1.37 52-week range 2.25
- YTD
- -29.81%
- 1 year
- -24.55%
News
businesswire.com Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca has updated the…
businesswire.com Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference.
defenseworld.net Innate Pharma (OTCMKTS:IPHYF) Stock Falls 32.9% – Here’s What Happened Innate Pharma SA (OTCMKTS:IPHYF - Get Free Report)'s share price dropped 32.9% on Friday. The stock traded as low as $1.5092 and last traded at $1.5092. Approximately 1,000 shares changed hands…
businesswire.com Innate Pharma Reports First Half 2026 Business Update and Financial Results MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results…
businesswire.com Innate Pharma Announces Conference Call and Webcast MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.
businesswire.com Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its…
businesswire.com Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®)…
businesswire.com Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC) Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983),…
businesswire.com Outcome of Innate Pharma's 2026 Annual General Meeting MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2026 Annual General Meeting.